TABLE 1.

MICs of cationic peptides and amikacin evaluated according to procedures outlined by the NCCLS and Hancock

Organisms (no. of strains)	Agentb	MIC (μg/ml)a
		Range		50%		90%
		NCCLS	Hancock	NCCLS	Hancock	NCCLS	Hancock
S. aureus (30)	BFII	2–64	0.5–8	8	2	32	8
	CP1	8–>128	4–128	64	16	>128	64
	IND	4–32	1–16	16	4	32	8
	MGII	4–128	1–64	16	8	128	32
	NS	2–64	1–16	16	4	32	8
	RNL	1–32	0.5–8	8	2	32	8
	AN	0.5–64	0.25–64	8	8	16	16
E. coli (30)	BFII	0.50–4	0.12–2	1	0.25	2	1
	CP1	0.12–4	0.12–2	1	0.25	4	1
	IND	0.5–8	0.25–8	4	2	8	8
	MGII	0.25–4	0.25–1	2	0.50	4	1
	NS	4–16	2–16	8	4	16	8
	RNL	1–32	0.25–32	8	4	32	16
	AN	0.06–8	0.06–8	2	2	8	8
P. aeruginosa (30)	BFII	2–128	0.50–16	16	4	32	8
	CP1	4–64	1–32	16	8	64	16
	IND	8–128	4–64	64	16	128	64
	MGII	2–128	0.50–32	16	8	128	32
	NS	16–128	4–128	64	32	128	128
	RNL	16–>128	8–128	64	32	>128	128
	AN	1–128	1–128	16	16	64	64

^a50% and 90%, MICs at which 50 and 90% of the strains are inhibited, respectively. 

^bBFII, buforin II; CP1, cecropin P1; IND, indolicidin; MGII, magainin II; NS, nisin; RNL, ranalexin; AN, amikacin.